PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Phenolic extracts from L. graveolens possess antioxidant and anti-inflammatory properties, significantly inhibiting DPPH radicals and regulating cytokines [PMID:36169085].
L. graveolens infusions and polyphenols-rich extracts showed concentration-dependent antiproliferative effects against MDA-MB-231 and MCF-7 cell lines [PMID:36014479, PMID:41097166].
Ethanolic extract of L. graveolens stem had a favorable effect on biochemical markers in a murine model of metabolic syndrome induced by monosodium glutamate [PMID:36117783].
Methanolic extract of L. graveolens exhibited a photochemopreventive effect against UVB radiation-induced skin cancer in SKH-1 mice [PMID:28039793].
Essential oil and carvacrol show synergistic effects when combined with imipenem against Acinetobacter baumannii and Pseudomonas aeruginosa [PMID:38786172]. It also inhibits A. baumannii biofilm formation [PMID:37887240].
Safety & adverse effects
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 34500592 (2021) — Mexican Oregano (Lippia graveolens Kunth) as Source of Bioactive Compounds: A Review. · Molecules (Basel, Switzerland)
- 2.PMID: 35012189 (2022) — Polyhydroxyalkanoates-Based Nanoparticles as Essential Oil Carriers. · Polymers
- 3.PMID: 11711112 (1998) — Iridoids from Lippia graveolens. · Phytochemistry
- 4.PMID: 16355848 (2005) — Antifungal activity of Mexican oregano (Lippia berlandieri Shauer). · Journal of food protection
- 5.PMID: 36014479 (2022) — Cytotoxic Activity of Polyphenol Extracts from Three Oregano Species: Hedeoma patens, Lippia graveolens and Lippia palmeri, and Antiproliferative Potential of Lippia graveolens against Two Types of Breast Cancer Cell Lines (MDA-MB-231 and MCF-7).